Pediatric pulmonary hypertension caregiver, Jennica Clasby shares her family's story. Jennica discusses the challenges of moving across country to sea level and leaving their support system behind in Colorado.
Boston native, Bill O'Donnell discusses the 15+ year journey his daughter Shannon has had with pulmonary hypertension. Bill shares his thoughts on the role of a being a pediatric caregiver and how battling PH is like running a marathon. Please also take a moment to read the letter he gave Shannon on her 15 year diagnosis anniversary (Bonus Content).
Dr. Steven Abman is Professor of Pediatrics and Director of the Pediatric Heart Lung Center (PHLC) at the University of Colorado Denver Anschutz School of Medicine and Children’s Hospital Colorado. Dr. Abman founded and continues to serve as Director of the Pediatric Pulmonary Hypertension Network (PPHNet), a multicenter clinical research and care group consisting of 10 leading PH centers from throughout North America, and initiated and led a joint American Heart Association/American Thoracic Society working group to establish the first joint guidelines for the care of children with pediatric pulmonary hypertension. Dr. Abman also serves on phaware’s Medical Advisory Board.
Dunbar Ivy, MD is currently the Section Head of Pediatric Cardiology and the Director of the Pediatric Pulmonary Hypertension Program at the University of Colorado. He has published over 100 medical articles, primarily focusing on pulmonary hypertension in children. He discusses the importance of Pediatric Pulmonary Hypertension Guidelines, the work of the Pediatric Pulmonary Hypertension Network (PPHNet.org) and how a PH Research app could change patient care.
Dr. Jeffrey Fineman is a pediatric critical care specialist, or intensivist, and the division chief of Critical Care at UCSF Benioff Children’s Hospital, San Francisco. He also is an investigator of the Cardiovascular Research Institute. His research has led to new therapies for pulmonary hypertension, including a drug called inhaled nitric oxide, which was approved by the U.S. Food and Drug Administration. Fineman's research has focused on diseases related to pulmonary circulation. In particular, he has been interested in the pathophysiology of pulmonary hypertension and heads a laboratory, funded by the National Institutes of Health, for these investigations.
Over the past decade, great strides have been made in the understanding of the pathobiology of pulmonary vascular disease, and from these findings new therapeutic options have emerged. It is increasingly clear that pulmonary vascular pathology is integral to a number of childhood disorders.
At the 10th International Conference Neonatal & Childhood Pulmonary Vascular Disease, chair's Jeffrey R. Fineman, MD and Ian Adatia, MBChB, FRCP will bring together international experts to explore their current understanding of the basic pathobiology as well as new and future therapies for neonatal, pediatric, and adult pulmonary vascular diseases. Learn more here.
Dr. Ian Adatia has spent the last 25 years helping to improve care for babies, children and young people with pulmonary vascular disease. He is a clinician scholar and researcher. He has developed innovative therapies for children with pulmonary hypertension, and the first childhood pulmonary hypertension clinic in North America.